Immunological cytokine profiling identifies TNF-α as a key molecule dysregulated in autistic children

Oncotarget

Volumn 8, Issue 47, 2017, Pages 82390-82398

  Xie, Jiang ^a,b   Huang, Li ^a,b   Li, Xiaohong ^c   Li, Hua ^a   Zhou, Yongmei ^a   Zhu, Hua ^a   Pan, Tianying ^c   Kendrick, Keith M ^d   Xu, Wenming ^c  

^a SOUTHWEST JIAOTONG UNIVERSITY   (China)

^b SOUTHWEST MEDICAL UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

^d UNIVERSITY OF ELECTRONIC SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Autism; Cytokines; LincRNA; THRIL mRNA; TNF

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN L; TUMOR NECROSIS FACTOR; UNTRANSLATED RNA;

AGE; ARTICLE; AUTISM; AUTISTIC BEHAVIOR CHECKLIST; BLOOD SAMPLING; CHECKLIST; CHILD; CHILD DEVELOPMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYMPTOM; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 85030855829     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.19326     Document Type: Article

References (46)

1. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T. Prevalence of disorders of the autism spectrum in a population of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet. 2006; 368:210-5.
2. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry. 2005; 162:1133-41.
3. Zhou WZ, Ye AY, Sun ZK, Tian HH, Pu TZ, Wu YY, Wang DD, Zhao MZ, Lu SJ, Yang CH, Wei L. Statistical analysis of twenty years (1993 to 2012) of data from mainland China's first intervention center for children with autism spectrum disorder. Mol Autism. 2014; 5:52.
4. Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The epidemiology and global burden of autism spectrum disorders. Psychol Med. 2015; 45:601-13.
5. Careaga M, Ashwood P. Autism spectrum disorders: from immunity to behavior. Methods Mol Biol. 2012; 934:219-40.
6. Kidd PM. Autism, an extreme challenge to integrative medicine. Part: 1: The knowledge base. Altern Med Rev. 2002; 7:292-316.
7. Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014; 383:896-910.
8. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med. 1995; 25:63-77.
9. Cohly HH, Panja A. Immunological findings in autism. Int Rev Neurobiol. 2005; 71:317-41.
10. Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002; 46:76-84.
11. Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology. 2005; 51:77-85.
12. Wong PH, White KM. Impact of immunoglobulin therapy in pediatric disease: a review of immune mechanisms. Clin Rev Allergy Immunol. 2016; 51:303-14.
13. Ferguson BJ, Marler S, Altstein LL, Lee EB, Mazurek MO, McLaughlin A, Macklin EA, McDonnell E, Davis DJ, Belenchia AM, Gillespie CH, Peterson CA, Bauman ML, et al. Associations between cytokines, endocrine stress response, and gastrointestinal symptoms in autism spectrum disorder. Brain Behav Immun. 2016; 58:57-62.
14. Masi A, Quintana DS, Glozier N, Lloyd AR, Hickie IB, Guastella AJ. Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry. 2015; 20:440-6.
15. Yang CJ, Tan HP, Yang FY, Liu CL, Sang B, Zhu XM, Du YJ. The roles of cortisol and pro-inflammatory cytokines in assisting the diagnosis of autism spectrum disorder. Res Autism Spectr Disord. 2015; 9:174-81.
16. Abdallah MW, Larsen N, Grove J, Nørgaard-Pedersen B, Thorsen P, Mortensen EL, Hougaard DM. Amniotic fluid inflammatory cytokines: potential markers of immunologic dysfunction in autism spectrum disorders. World J Biol Psychiatry. 2013; 14:528-38.
17. Jones KL, Croen LA, Yoshida CK, Heuer L, Hansen R, Zerbo O, DeLorenze GN, Kharrazi M, Yolken R, Ashwood P, Van de Water J. Autism with intellectual disability is associated with increased levels of maternal cytokines and chemokines during gestation. Mol Psychiatry. 2017; 22:273-9.
18. Krakowiak P, Goines PE, Tancredi DJ, Ashwood P, Hansen RL, Hertz-Picciotto I, Van de Water J. Neonatal cytokine profiles associated with autism spectrum disorder. Biol Psychiatry. 2017; 81:442-51.
19. Lee RH, Mills EA, Schwartz N, Bell MR, Deeg KE, Ruthazer ES, Marsh-Armstrong N, Aizenman CD. Neurodevelopmental effects of chronic exposure to elevated levels of pro-inflammatory cytokines in a developing visual system. Neural Dev. 2010; 5:2.
20. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, Ji L, Brown T, Malik M. Elevated immune response in the brain of autistic patients. J Neuroimmunol. 2009; 207:111-6.
21. Malik M, Sheikh AM, Wen G, Spivack W, Brown WT, Li X. Expression of inflammatory cytokines, Bcl2 and cathepsin D are altered in lymphoblasts of autistic subjects. Immunobiology. 2011; 216:80-5.
22. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005; 57:67-81.
23. Xu N, Li X, Zhong Y. Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediators Inflamm. 2015; 2015:531518.
24. Li Z, Chao TC, Chang KY, Lin N, Patil VS, Shimizu C, Head SR, Burns JC, Rana TM. The long noncoding RNA THRIL regulates TNFa expression through its interaction with hnRNPL. Proc Natl Acad Sci U S A. 2014; 111:1002-7.
25. Goldstein S, Naglieri JA. Encyclopedia of Child Behavior and Development. Springer US. 2011, 10-11.
26. Shen Y, Ou J, Liu M, Shi L, Li Y, Xiao L, Dong H, Zhang F, Xia K, Zhao J. Altered plasma levels of chemokines in autism and their association with social behaviors. Psychiatry Res. 2016; 244:300-5.
27. Arrode-Brusés G, Brusés JL. Maternal immune activation by poly I:C induces expression of cytokines IL-1β and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain. J Neuroinflammation. 2012; 9:83.
28. Brown AS. Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Dev Neurobiol. 2012; 72:1272-6.
29. Parker-Athill EC, Tan J. Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway. Neurosignals. 2010; 18:113-28.
30. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007; 27:10695-702.
31. Ziats MN, Rennert OM. Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways. PLoS One. 2011; 6:e24691.
32. Bauman MD, Iosif AM, Smith SE, Bregere C, Amaral DG, Patterson PH. Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. Biol Psychiatry. 2014; 75:332-41.
33. Forrest CM, Khalil OS, Pisar M, Smith RA, Darlington LG, Stone TW. Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring. Mol Brain. 2012; 5:22.
34. Banks WA. The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav Immun. 2015; 44:1-8.
35. Walker CK, Krakowiak P, Baker A, Hansen RL, Ozonoff S, Hertz-Picciotto I. Preeclampsia, placental insufficiency, and autism spectrum disorder or developmental delay. JAMA Pediatr. 2015; 169:154-62.
36. Gorrindo P, Williams KC, Lee EB, Walker LS, McGrew SG, Levitt P. Gastrointestinal dysfunction in autism: parental report, clinical evaluation, and associated factors. Autism Res. 2012; 5:101-8.
37. Pate AB, Tsilioni I, Leeman SE, Theoharides TC. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proc Natl Acad Sci U S A. 2016; 113:7049-58.
38. Zhang B, Zou J, Han L, Rensing N, Wong M. Microglial activation during epileptogenesis in a mouse model of tuberous sclerosis complex. Epilepsia. 2016; 57:1317-25.
39. Borsini A, Zunszain PA, Thuret S, Pariante CM. The role of inflammatory cytokines as key modulators of neurogenesis. Trends Neurosci. 2015; 38:145-57.
40. Packer A. Neocortical neurogenesis and the etiology of autism spectrum disorder. Neurosci Biobehav Rev. 2016; 64:185-95.
41. Felice C, Marzo M, Pugliese D, Papa A, Rapaccini GL, Guidi L, Armuzzi A. Therapeutic drug monitoring of anti-TNF-a agents in inflammatory bowel diseases. Expert Opin Biol Ther. 2015; 15:1107-17.
42. Oda K, Minata M. Drug free remission after steroiddependent disappearance of lymphoproliferative disorder in rheumatoid arthritis patient treated with TNF-a blockade: case study. Springer plus. 2015; 4:1-5.
43. Cheng X, Shen Y, Li R. Targeting TNF: a therapeutic strategy for Alzheimer's disease. Drug Discov Today. 2014; 19:1822-7.
44. Burton A, Kizhner O, Brown MB, Peltier MR. Effect of experimental genital mycoplasmosis on gene expression in the fetal brain. J Reprod Immunol. 2015; 93:9-16.
45. Di Marco B, Bonaccorso CM, Aloisi E, D'Antoni S, Catania MV. Neuro-inflammatory mechanisms in developmental disorders associated with intellectual disability and autism spectrum disorder: a neuro-immune perspective. CNS Neurol Disord Drug Targets. 2016; 15:448-63.
46. Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, Hoeffer CA, Littman DR, Huh JR. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science. 2016; 351:933-9.